{"id":"alemtuzumab-infusion","safety":{"commonSideEffects":[{"rate":"50-90","effect":"Infusion reactions (fever, chills, hypotension)"},{"rate":"high","effect":"Lymphopenia"},{"rate":"30-50","effect":"Infections (opportunistic and bacterial)"},{"rate":"10-30","effect":"Autoimmune complications (thyroiditis, ITP)"},{"rate":"20-40","effect":"Nausea and vomiting"},{"rate":"10-20","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1201587","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Alemtuzumab targets CD52, a glycoprotein expressed on B lymphocytes, T lymphocytes, and other immune cells. Upon binding, it triggers antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), resulting in rapid lymphocyte depletion. This immunosuppressive effect is used to treat autoimmune conditions and certain hematologic malignancies.","oneSentence":"Alemtuzumab is a monoclonal antibody that binds to CD52 on the surface of lymphocytes, leading to their destruction and depletion of T and B cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:25:12.571Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing-remitting multiple sclerosis"},{"name":"Chronic lymphocytic leukemia (CLL)"},{"name":"T-cell prolymphocytic leukemia"}]},"trialDetails":[{"nctId":"NCT06959771","phase":"PHASE1, PHASE2","title":"Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-07-16","conditions":"CD40L-HyperIgM Syndrome","enrollment":1},{"nctId":"NCT05463133","phase":"PHASE1, PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-07-08","conditions":"Chronic Granulomatous Disease","enrollment":50},{"nctId":"NCT00920972","phase":"PHASE1, PHASE2","title":"Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2001-12","conditions":"Metabolic Disorders, Hematologic, Immune, or Bone Marrow Disorders, Hemoglobinopathies","enrollment":220},{"nctId":"NCT03910452","phase":"EARLY_PHASE1","title":"Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-10-28","conditions":"Chronic Granulomatous Disease","enrollment":4},{"nctId":"NCT05357482","phase":"PHASE1, PHASE2","title":"Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-05-12","conditions":"Sickle Cell Anemia, Beta Thalassemia","enrollment":40},{"nctId":"NCT06872333","phase":"PHASE2","title":"Allo HSCT for High Risk Hemoglobinopathies","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-11-19","conditions":"Graft Failure, Sickle Cell Disease, Hemoglobinopathies","enrollment":62},{"nctId":"NCT00619528","phase":"NA","title":"HLA-Identical Sibling Renal Transplant Tolerance","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2008-01","conditions":"Immunosuppression, Kidney Transplantation, Graft Rejection","enrollment":88},{"nctId":"NCT01821781","phase":"PHASE2","title":"Immune Disorder HSCT Protocol","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2013-04-29","conditions":"Immune Deficiency Disorders, Severe Combined Immunodeficiency, Chronic Granulomatous Disease","enrollment":20},{"nctId":"NCT03504241","phase":"PHASE1","title":"Tolerance by Engaging Antigen During Cellular Homeostasis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-07-30","conditions":"Kidney Transplantation, Renal Transplantation, Renal Transplant Recipient","enrollment":8},{"nctId":"NCT01625351","phase":"PHASE1","title":"A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2012-08-20","conditions":"Ewing Sarcoma, Gastrointestinal Tumor, Germ Cell Tumor","enrollment":23},{"nctId":"NCT03579875","phase":"PHASE2","title":"Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2018-11-13","conditions":"Fanconi Anemia, Severe Aplastic Anemia, Myelodysplastic Syndromes","enrollment":48},{"nctId":"NCT01652092","phase":"NA","title":"Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2012-09-04","conditions":"SCID, Omenn's Syndrome, Reticular Dysgenesis","enrollment":57},{"nctId":"NCT02171104","phase":"PHASE2","title":"MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2014-07-10","conditions":"Mucopolysaccharidosis Disorders, Hurler Syndrome, Hunter Syndrome","enrollment":149},{"nctId":"NCT04047628","phase":"PHASE3","title":"Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-19","conditions":"Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis","enrollment":156},{"nctId":"NCT05384756","phase":"PHASE1","title":"TMLI and Alemtuzumab for Treatment of Sickle Cell Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2022-07-13","conditions":"Sickle Cell Disease","enrollment":2},{"nctId":"NCT06145282","phase":"PHASE1, PHASE2","title":"Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2023-12-28","conditions":"Sickle Cell Disease","enrollment":6},{"nctId":"NCT00692939","phase":"PHASE1, PHASE2","title":"Autologous Stem Cell Transplantation for Crohn's Disease","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2012-06-26","conditions":"Crohn's Disease","enrollment":20},{"nctId":"NCT04232085","phase":"PHASE2","title":"Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2020-02-12","conditions":"Primary Immune Deficiency Disorder, Immune Deficiency Disease, Bone Marrow Failure","enrollment":27},{"nctId":"NCT06358638","phase":"PHASE2","title":"Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody","status":"RECRUITING","sponsor":"Children's National Research Institute","startDate":"2024-04-03","conditions":"Sickle Cell Disease","enrollment":12},{"nctId":"NCT04339777","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-22","conditions":"Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Immune System Diseases","enrollment":66},{"nctId":"NCT05600907","phase":"EARLY_PHASE1","title":"Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-01-02","conditions":"Chronic Granulomatous Disease, CGD","enrollment":7},{"nctId":"NCT01889381","phase":"PHASE2","title":"Human Craniomaxillofacial Allotransplantation","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2012-08","conditions":"Facial Injuries, Traumatic Wounds and Injuries, Craniofacial Injuries","enrollment":15},{"nctId":"NCT04362293","phase":"PHASE2","title":"Reduced Intensity Transplantation for Severe Sickle Cell Disease","status":"SUSPENDED","sponsor":"St. Jude Children's Research Hospital","startDate":"2020-04-30","conditions":"Sickle Cell Disease","enrollment":40},{"nctId":"NCT07015684","phase":"PHASE1","title":"131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)","status":"RECRUITING","sponsor":"Columbia University","startDate":"2025-04-28","conditions":"Sickling Disorder Due to Hemoglobin S","enrollment":24},{"nctId":"NCT01459107","phase":"PHASE2","title":"Human Upper Extremity Allotransplantation","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2011-07-21","conditions":"Amputation, Traumatic, Wounds and Injuries, Hand Injuries","enrollment":30},{"nctId":"NCT01499888","phase":"PHASE1, PHASE2","title":"Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2011-11-11","conditions":"Sickle Cell Disease","enrollment":45},{"nctId":"NCT02105766","phase":"PHASE2","title":"Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2014-04-21","conditions":"Sickle Cell Disease, Thalassemia, Stem Cell Transplantation","enrollment":56},{"nctId":"NCT02179359","phase":"NA","title":"Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2014-09-02","conditions":"Sickle Cell Disease, Transfusion Dependent Alpha- or Beta- Thalassemia, Diamond Blackfan Anemia","enrollment":38},{"nctId":"NCT02165007","phase":"PHASE1","title":"Haploidentical Hematopoietic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Catherine Bollard","startDate":"2015-01","conditions":"Sickle Cell-thalassemia Disease, Thalassemia","enrollment":7},{"nctId":"NCT03077542","phase":"PHASE1, PHASE2","title":"Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2017-04-06","conditions":"Sickle Cell Disease","enrollment":57},{"nctId":"NCT01050855","phase":"PHASE2","title":"Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2008-01","conditions":"Non Malignant Diseases, Immunodeficiencies, Hemoglobinopathies","enrollment":75},{"nctId":"NCT02867800","phase":"PHASE1","title":"Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease","status":"COMPLETED","sponsor":"Monica Bhatia","startDate":"2016-07","conditions":"Sickle Cell Disease, Graft Versus Host Disease","enrollment":24},{"nctId":"NCT02061800","phase":"PHASE1, PHASE2","title":"CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Diane George","startDate":"2013-06-03","conditions":"Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS)","enrollment":14},{"nctId":"NCT03821610","phase":"PHASE2","title":"A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Birmingham","startDate":"2018-11-22","conditions":"Acute Lymphoblastic Leukemia","enrollment":242},{"nctId":"NCT04633967","phase":"","title":"Observational Study of a Novel Peri Infusion Regimen on the Infusion Associated Reactions With Alemtuzumab Infusion in Patients With Multiple Sclerosis in a Canadian Clinical Setting.","status":"COMPLETED","sponsor":"Maritime Neurology","startDate":"2016-05-15","conditions":"Frequency of Infusion Reactions in Novel Versus Standard Protocol in Multiple Sclerosis","enrollment":30},{"nctId":"NCT00061568","phase":"PHASE1, PHASE2","title":"Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias","status":"UNKNOWN","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2004-07-16","conditions":"Congenital Hemolytic Anemia, Sickle Cell Disease","enrollment":130},{"nctId":"NCT01172418","phase":"PHASE4","title":"Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols","status":"COMPLETED","sponsor":"University of Miami","startDate":"2006-02","conditions":"Transplant; Failure, Kidney","enrollment":200},{"nctId":"NCT00074282","phase":"PHASE2","title":"Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2005-04-14","conditions":"Leukemia","enrollment":102},{"nctId":"NCT01877837","phase":"PHASE3","title":"Stem Cell Transplantation for Sickle Cell Anemia","status":"COMPLETED","sponsor":"Hackensack Meridian Health","startDate":"2011-06","conditions":"Sickle Cell Disease","enrollment":30},{"nctId":"NCT03421756","phase":"EARLY_PHASE1","title":"Stem Cell Transplant in Patients With Severe Sickle Cell Disease","status":"TERMINATED","sponsor":"Kathleen Dorritie","startDate":"2018-03-29","conditions":"Sickle Cell Disease","enrollment":1},{"nctId":"NCT01982175","phase":"PHASE2","title":"Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia","status":"SUSPENDED","sponsor":"Shanghai Zhangjiang Biotechnology Limited Company","startDate":"2011-07","conditions":"B-cell Chronic Lymphocytic Leukemia","enrollment":120},{"nctId":"NCT00345345","phase":"PHASE2","title":"Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2006-10-17","conditions":"T-LGL Lymphoproliferative Disorders","enrollment":29},{"nctId":"NCT03774914","phase":"","title":"LEMTRADA Pregnancy Registry in Multiple Sclerosis","status":"TERMINATED","sponsor":"Genzyme, a Sanofi Company","startDate":"2015-09-01","conditions":"Multiple Sclerosis","enrollment":42},{"nctId":"NCT02255656","phase":"PHASE4","title":"Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2015-01-07","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":1062},{"nctId":"NCT03135249","phase":"PHASE4","title":"Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2018-05-01","conditions":"Multiple Sclerosis (MS)","enrollment":9},{"nctId":"NCT02678143","phase":"PHASE1","title":"Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2016-04-26","conditions":"Sickle Cell Disease","enrollment":1},{"nctId":"NCT02419378","phase":"PHASE4","title":"Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential","status":"COMPLETED","sponsor":"University Hospital Muenster","startDate":"2015-06","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":15},{"nctId":"NCT02435901","phase":"PHASE1, PHASE2","title":"HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2008-12","conditions":"Sickle Cell Disease, Beta Thalassemia-Major","enrollment":29},{"nctId":"NCT00881556","phase":"EARLY_PHASE1","title":"Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)","status":"TERMINATED","sponsor":"Columbia University","startDate":"2009-08-20","conditions":"Epidermolysis Bullosa","enrollment":3},{"nctId":"NCT01729494","phase":"PHASE4","title":"Belatacept Early Steroid Withdrawal Trial","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2012-09","conditions":"Renal Transplantation","enrollment":316},{"nctId":"NCT00065260","phase":"PHASE2","title":"Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2003-11-06","conditions":"Aplastic Anemia","enrollment":54},{"nctId":"NCT02583594","phase":"PHASE1","title":"A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2015-12-06","conditions":"Progressive Multiple Sclerosis","enrollment":24},{"nctId":"NCT00777231","phase":"PHASE1, PHASE2","title":"Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies","status":"COMPLETED","sponsor":"Talaris Therapeutics Inc.","startDate":"2005-01","conditions":"Sickle Cell Disease","enrollment":9},{"nctId":"NCT00536978","phase":"PHASE2","title":"Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-09","conditions":"Lymphoma, Leukemia","enrollment":22},{"nctId":"NCT00578344","phase":"NA","title":"Bone Marrow Transplantation, Hemoglobinopathies, SCALLOP","status":"TERMINATED","sponsor":"Tami D. John","startDate":"2005-07","conditions":"Sickle Cell Disease, Hemoglobin SC","enrollment":8},{"nctId":"NCT00578292","phase":"NA","title":"Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2004-02","conditions":"Thalassemia","enrollment":10},{"nctId":"NCT00566696","phase":"PHASE2","title":"Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2007-12-14","conditions":"Leukemia, Acute Lymphocytic (ALL), Leukemia, Myeloid, Acute(AML), Leukemia, Myeloid, Chronic(CML)","enrollment":73},{"nctId":"NCT00176852","phase":"PHASE2, PHASE3","title":"Stem Cell Transplant for Hemoglobinopathy","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2002-06","conditions":"Sickle Cell Disease, Thalassemia, Severe Congenital Neutropenia","enrollment":22},{"nctId":"NCT00565773","phase":"PHASE2","title":"Belatacept Post Depletional Repopulation to Facilitate Tolerance","status":"COMPLETED","sponsor":"Allan D Kirk, MD, PhD","startDate":"2007-12","conditions":"Organ Transplantation","enrollment":40},{"nctId":"NCT02411084","phase":"PHASE3","title":"Study of BEGEDINA® vs \"Conventional Treatment\" for Treating Steroid-Resistant Acute GvHD","status":"TERMINATED","sponsor":"Adienne SA","startDate":"2016-02","conditions":"Graft vs Host Disease","enrollment":36},{"nctId":"NCT00368355","phase":"PHASE2","title":"T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2000-04","conditions":"Acute Lymphoblastic Leukemia, Non Hodgkins Lymphoma, Myelodysplastic Syndrome","enrollment":46},{"nctId":"NCT00048412","phase":"PHASE1, PHASE2","title":"Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2000-06","conditions":"Myelodysplastic Disorders, Leukemia, Multiple Myeloma","enrollment":40},{"nctId":"NCT04154735","phase":"PHASE2","title":"Autologous Transplant Targeted Against Crohn's","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2019-11","conditions":"Crohn's Disease","enrollment":""},{"nctId":"NCT01013441","phase":"PHASE1","title":"CD3/CD28 Bead Activated T-Cells Following Chemo-Immunotherapy in Patients With Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2009-03","conditions":"Chronic Lymphocytic Leukemia","enrollment":20},{"nctId":"NCT04082260","phase":"","title":"Signatures of Immune Reprogramming in Anti-CD52 Therapy of MS: Markers for Risk Stratification and Treatment Response","status":"UNKNOWN","sponsor":"University Hospital Muenster","startDate":"2017-01","conditions":"Multiple Sclerosis","enrollment":150},{"nctId":"NCT02013375","phase":"PHASE2","title":"SCD-Haplo: Phase II Study of HLA-Haploidentical SCT for Aggressive SCD","status":"TERMINATED","sponsor":"Damiano Rondelli, MD","startDate":"2014-04-10","conditions":"Sickle Cell Disease","enrollment":2},{"nctId":"NCT00775931","phase":"PHASE2, PHASE3","title":"Allogeneic Transplantation For Severe Osteopetrosis","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2008-08","conditions":"Severe Osteopetrosis","enrollment":7},{"nctId":"NCT01875237","phase":"PHASE1, PHASE2","title":"Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-12-27","conditions":"Leukemia, Myeloma, Myeloproliferative Diseases","enrollment":3},{"nctId":"NCT00383448","phase":"PHASE2","title":"HSCT for High Risk Inherited Inborn Errors","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2006-09","conditions":"Adrenoleukodystrophy, Metachromatic Leukodystrophy, Globoid Cell Leukodystrophy","enrollment":38},{"nctId":"NCT00634881","phase":"PHASE1, PHASE2","title":"Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"German CLL Study Group","startDate":"2003-11","conditions":"Chronic Lymphocytic Leukemia","enrollment":13},{"nctId":"NCT00801931","phase":"PHASE1, PHASE2","title":"Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders","status":"TERMINATED","sponsor":"Columbia University","startDate":"2007-09-06","conditions":"Leukemia, Lymphoma, Neuroblastoma","enrollment":1},{"nctId":"NCT00520130","phase":"PHASE1, PHASE2","title":"Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-10-30","conditions":"Myelodysplastic Syndrome, Hodgkin's Lymphoma, Non-Hodgkin's Disease","enrollment":92},{"nctId":"NCT00057967","phase":"PHASE2","title":"Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary Syndrome","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2000-07","conditions":"Lymphoma","enrollment":37},{"nctId":"NCT00943319","phase":"PHASE1, PHASE2","title":"Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2012-03","conditions":"Leukemia, Lymphoma, Myeloma","enrollment":50},{"nctId":"NCT01395316","phase":"PHASE4","title":"Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2011-06","conditions":"Multiple Sclerosis","enrollment":8},{"nctId":"NCT00578643","phase":"PHASE2","title":"Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2004-03","conditions":"Chronic Granulomatous Disease","enrollment":15},{"nctId":"NCT01307332","phase":"PHASE3","title":"Advanced MRI Measures of Repair in Alemtuzumab Treated Patients","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2011-03","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":27},{"nctId":"NCT00331162","phase":"PHASE4","title":"Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2005-02","conditions":"Graft Rejection","enrollment":222},{"nctId":"NCT01049854","phase":"PHASE2","title":"CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant","status":"COMPLETED","sponsor":"New York Medical College","startDate":"2011-09","conditions":"Leukemia, Lymphoma, Bone Marrow Failure","enrollment":20},{"nctId":"NCT00078559","phase":"PHASE1, PHASE2","title":"Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2003-11","conditions":"Kidney Transplantation, Kidney Disease","enrollment":10},{"nctId":"NCT00590460","phase":"PHASE1, PHASE2","title":"Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2001-07","conditions":"Fanconi Anemia, Severe Aplastic Anemia","enrollment":5},{"nctId":"NCT00626626","phase":"PHASE1, PHASE2","title":"Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation","status":"TERMINATED","sponsor":"Milton S. Hershey Medical Center","startDate":"2007-05","conditions":"Leukemia, Myelodysplastic Syndrome, Chronic Myelogenous Leukemia","enrollment":8},{"nctId":"NCT01043640","phase":"PHASE2","title":"Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2009-12","conditions":"Mucopolysaccharidosis, Hurler Syndrome, Hunter Syndrome","enrollment":46},{"nctId":"NCT02701517","phase":"PHASE2","title":"Cyclosporine Plus Methotrexate or Alemtuzumab","status":"TERMINATED","sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","startDate":"2003-09","conditions":"Unrecognized Condition: Mature B or T-cell Neoplasm","enrollment":72},{"nctId":"NCT00176865","phase":"PHASE2","title":"Stem Cell Transplant for Immunologic or Histiocytic Disorders","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2002-08","conditions":"Hemophagocytic Lymphohistiocytosis, X-Linked Lymphoproliferative Disorders, Chediak-Higashi Syndrome","enrollment":19},{"nctId":"NCT00638820","phase":"PHASE2","title":"Reduced Intensity AlloTransplant For Osteopetrosis","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2007-09","conditions":"Osteopetrosis","enrollment":3},{"nctId":"NCT01005576","phase":"PHASE2","title":"Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2010-01","conditions":"Severe Thalassemia","enrollment":21},{"nctId":"NCT01626092","phase":"NA","title":"Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2012-07-11","conditions":"Lysosomal Storage Disease, Peroxisomal Disorder","enrollment":3},{"nctId":"NCT00455312","phase":"PHASE2, PHASE3","title":"Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2007-08","conditions":"Dyskeratosis Congenita, Aplastic Anemia","enrollment":36},{"nctId":"NCT00301834","phase":"PHASE2","title":"Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2005-01","conditions":"Congenital Amegakaryocytic Thrombocytopenia, Diamond-blackfan Anemia, Leukemia","enrollment":35},{"nctId":"NCT00416884","phase":"PHASE2","title":"Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2003-05","conditions":"Leukemia","enrollment":1},{"nctId":"NCT02653196","phase":"EARLY_PHASE1","title":"A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors","status":"TERMINATED","sponsor":"Montefiore Medical Center","startDate":"2015-09","conditions":"Neuroepithelial Tumor, Solid Tumor, Allogeneic Hematopoietic Stem Cell Transplantation","enrollment":1},{"nctId":"NCT00281983","phase":"PHASE1, PHASE2","title":"Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia","status":"COMPLETED","sponsor":"German CLL Study Group","startDate":"2000-06","conditions":"Chronic Lymphocytic Leukemia","enrollment":100},{"nctId":"NCT00448357","phase":"PHASE1, PHASE2","title":"Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2005-10","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":54},{"nctId":"NCT03193086","phase":"","title":"The Effect of Alemtuzumab on the Blood-brain-barrier and the Brain's Metabolism in Multiple Sclerosis Patients","status":"UNKNOWN","sponsor":"Glostrup University Hospital, Copenhagen","startDate":"2017-01-01","conditions":"Multiple Sclerosis","enrollment":35},{"nctId":"NCT01757574","phase":"PHASE4","title":"Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD)","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2012-11","conditions":"Chronic Inflammatory Demyelinating Neuropathy","enrollment":""},{"nctId":"NCT00930553","phase":"PHASE3","title":"An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2009-08","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":1314},{"nctId":"NCT00548405","phase":"PHASE3","title":"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2007-10","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":840},{"nctId":"NCT00698685","phase":"PHASE2","title":"Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation","status":"TERMINATED","sponsor":"University of Arizona","startDate":"2006-01-23","conditions":"Leukemia, Lymphoma, Hodgkin's Disease","enrollment":14},{"nctId":"NCT00578266","phase":"PHASE1","title":"Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2007-02","conditions":"Anemia, Aplastic","enrollment":8}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":42,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Alemtuzumab infusion","genericName":"Alemtuzumab infusion","companyName":"Johns Hopkins University","companyId":"johns-hopkins-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Alemtuzumab is a monoclonal antibody that binds to CD52 on the surface of lymphocytes, leading to their destruction and depletion of T and B cells. Used for Relapsing-remitting multiple sclerosis, Chronic lymphocytic leukemia (CLL), T-cell prolymphocytic leukemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}